Live Chat

交易 Vir Biotechnology VIR

出售
 購買

VirBiotechnology實時圖表

5m 15m 30m 1h 4h 1d 1w

金融工具基礎知識

Weekly Search
Weekly
Daily
日期  關閉 更改 更改(%)： 開倉 高 低

最新新聞

Christine Voong 2025 Jan 17, 08:55

比特幣價格走勢突破10萬美元創新高！川普政策預期推動加密貨幣市場上漲

Christine Voong 2025 Jan 17, 07:45

黃金價格走勢持穩接近一個月高點：利率政策與川普新政成關鍵變數

Christine Voong 2025 Jan 17, 05:40

亞洲股市漲跌互見，中國經濟數據提振股市走高，日本股市因加息預期下跌

Christine Voong 2025 Jan 17, 04:50

蘋果股價下跌失去中國銷量領先地位，美股指數期貨小幅下滑

So Ze Dong 2025 Jan 16, 16:00

美股結束三連漲，蘋果領跌科技板塊，企業財報強勁但市場疲弱

Christine Voong 2025 Jan 16, 06:20

亞洲股市上漲，美國通脹數據放緩促使全球股市上揚，南韓央行維持利率不變

Christine Voong 2025 Jan 16, 04:30

原油價格走勢攀升，受美國原油庫存下降、溫和通脹數據及對俄制裁推動

Christine Voong 2025 Jan 16, 03:15

美股指數期貨小幅上揚，銀行財報強勁與通膨數據放緩提振市場信心，川普政策不確定性影響市場情緒

聯絡方式

點差

0.08

點差(%)

0.7937 %

槓桿

1:10

隔夜利息（買入）

-0.0597 %

隔夜利息（賣出）

-0.0292 %

貨幣

USD

交易時間

市場關閉

星期二

14:31 - 20:59

星期三

14:31-20:59

星期四

14:31-20:59

星期五

14:31-20:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

1384086016

流通股份

137720000

收益日期（下一個）

0000-00-00

現金殖利率 

除息日

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-3.93

了解有關此金融工具的詳細資訊

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

相關工具

資產
出售
購買
更改(%)：

立即交易

立即交易

立即交易

立即交易
查看所有金融工具
Trustpilot
Live Chat